Eli Lilly and Company reported positive topline results from its Phase 3 ADorable-1 trial for EBGLYSS (lebrikizumab-lbkz). The study evaluated pediatric patients aged six months to 18 years with moderate-to-severe atopic dermatitis.
EBGLYSS met its primary and key secondary endpoints at Week 16, demonstrating improved skin clearance and itch relief. Approximately 63% of patients achieved at least a 75% improvement in the Eczema Area and Severity Index (EASI-75). Clear or almost clear skin was achieved by 44% of participants.
Lilly plans to submit these data to global regulators for a potential label update for the selective IL-13 inhibitor. The safety profile remained consistent with previous studies involving adults and adolescents.